1. Home
  2. DAVA vs VYGR Comparison

DAVA vs VYGR Comparison

Compare DAVA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$4.16

Market Cap

220.4M

Sector

Technology

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.85

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAVA
VYGR
Founded
2000
2013
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.4M
227.2M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
DAVA
VYGR
Price
$4.16
$3.85
Analyst Decision
Buy
Strong Buy
Analyst Count
9
2
Target Price
$13.50
$16.50
AVG Volume (30 Days)
216.5K
488.9K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$34.04
Revenue Next Year
$4.07
$7.92
P/E Ratio
$20.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$2.65
52 Week High
$20.80
$5.55

Technical Indicators

Market Signals
Indicator
DAVA
VYGR
Relative Strength Index (RSI) 40.04 47.72
Support Level N/A $3.72
Resistance Level $7.04 $4.31
Average True Range (ATR) 0.22 0.16
MACD -0.03 -0.02
Stochastic Oscillator 17.43 31.91

Price Performance

Historical Comparison
DAVA
VYGR

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: